Login to Your Account

Financings Roundup

Bolstering Cash Position, YM Raises $40M in Public Offering

By Jennifer Boggs

Wednesday, December 15, 2010
Coming off a good showing at the American Society of Hematology meeting in Orlando, Fla., where its JAK inhibitor CYT387 impressed in myelofibrosis, YM BioSciences Inc. is padding its coffers with a $40 million public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription